

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

Χριστίνα Μητροπούλου, PhD, MBA

Μάρτιος 2025

ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ

Όνομα: **Χριστίνα**

Επώνυμο: **Μητροπούλου**

Διεύθυνση: **Λοχαγού Χρονοπούλου 8, Άλιμος, 174 55, Αθήνα**

E-mail: c.mitropoulou@goldenhelix.org

Εθνικότητα: **Ελληνική**

ΕΚΠΑΙΔΕΥΣΗ

1996: *B.Sc. στις Οικονομικές Επιστήμες* – Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Σχολή Οικονομικών Επιστημών, Αθήνα

2000: *Master in Business Administration (MBA)* – NIMBAS University School of Business, Utrecht, the Netherlands.

2020: *Ph.D.in Health Economics* – Erasmus University Medical Center, Rotterdam, the Netherlands.

2021 – ΣΗΜΕΡΑ: *Μεταδιδακτορική Ερευνήτρια* – The Golden Helix Foundation, London, UK

ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΕΜΠΕΙΡΙΑ

- **ΟΚΤΩΒΡΙΟΣ 2022 – ΣΗΜΕΡΑ:** *Άμισθη Επισκέπτρια Επίκουρη Καθηγήτρια (Adjunct Assistant Professor)*, United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics, Al-Ain, Abu Dhabi, UAE
- **ΙΟΥΝΙΟΣ 2022 – ΣΗΜΕΡΑ:** *Μέλος του Γνωμοδοτικού Συμβουλίου*, PharmGenHub Consortium (<https://pharmgenhub.rs/about-us/advisory-board/>).
- **ΙΑΝΟΥΑΡΙΟΣ 2016 – ΣΗΜΕΡΑ:** *Μέλος του Εκτελεστικού Συμβουλίου*, Ubiquitous Pharmacogenomics Consortium (<https://upgx.eu/u-pgx-consortium/>).
- **ΔΕΚΕΜΒΡΙΟΣ 2009 – ΣΗΜΕΡΑ:** *Οικονομολόγος Υγείας*, The Golden Helix Foundation, Capital Tower, 6th floor, 91 Waterloo Road, London, SE1 8RT, United Kingdom.
- **ΣΕΠΤΕΜΒΡΙΟΣ 2001 – ΣΕΠΤΕΜΒΡΙΟΣ 2008:** *Account Manager*, Exact Software BV, Delft, the Netherlands.
- **ΙΟΥΝΙΟΣ 1999 – ΣΕΠΤΕΜΒΡΙΟΣ 1999:** *Intern*, Wadinson Consultants Ltd., Nicosia, Cyprus.

ΕΚΠΑΙΔΕΥΤΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ

- **ΦΕΒΡΟΥΑΡΙΟΣ 2025 – ΣΗΜΕΡΑ:** *Εντεταλμένη Διδάσκουσα*, Πανεπιστήμιο Ιωαννίνων, Τμήμα Οικονομικών Επιστημών, Προπτυχιακό Πρόγραμμα Σπουδών,

Αυτοδύναμη ανάθεση διδασκαλίας μαθήματος επιλογής «Οικονομικά της Υγείας» 8^{ου} εξαμήνου.

- **ΟΚΤΩΒΡΙΟΣ 2023 – ΣΗΜΕΡΑ: Διδάσκουσα**, Δημοκρίτειο Πανεπιστήμιο Θράκης, Τμήμα Μοριακής Βιολογίας και Γενετικής, Μεταπτυχιακό Πρόγραμμα «Μεταφραστική Έρευνα στην Βιοϊατρική» (διδασκαλία της ενότητας «Οικονομικά της Υγείας και επιχειρηματικότητα»).
- **ΟΚΤΩΒΡΙΟΣ 2022 – ΣΗΜΕΡΑ: Διδάσκουσα**, United Arab Emirates University, Department of Genetics and Genomics (διδασκαλία μεταπτυχιακών μαθημάτων στα οικονομικά της υγείας και συνεπίβλεψη εργασιών μεταπτυχιακών φοιτητών).
- **ΟΚΤΩΒΡΙΟΣ 2022 – ΣΗΜΕΡΑ: Διδάσκουσα**, Πανεπιστήμιο Πατρών, Σχολή Επιστημών Υγείας, Μεταπτυχιακό Πρόγραμμα «Εξατομικευμένη Ιατρική» (διδασκαλία της ενότητας «οικονομικά της υγείας στην εξατομικευμένη ιατρική»).
- **ΟΚΤΩΒΡΙΟΣ 2021 – ΣΗΜΕΡΑ: Διδάσκουσα**, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Σχολή Επιστημών Υγείας, Μεταπτυχιακό Πρόγραμμα «Ιατρική Ακριβείας» (διδασκαλία της ενότητας «οικονομικά της υγείας στην εξατομικευμένη ιατρική»).
- **ΣΕΠΤΕΜΒΡΙΟΣ 2014 – ΣΗΜΕΡΑ: Διδάσκουσα**, The Golden Helix Academy (διδασκαλία και αξιολόγηση μαθημάτων με τίτλους (α) Economic Evaluation in Healthcare Systems (Health Technology Assessment, economic evaluation in Genomic Medicine), (β) Health Economics and Decision Making (Pharmaceutical Price Regulation and Reimbursement, Economics for healthcare professionals, Health Economics, insurance)).

ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΕΙΩΝ

- Σύνδεσμος Ιατρικών Γενετιστών Ελλάδας (ΣΙΓΕ)
- Ελληνική Εταιρεία Βιολογικών Επιστημών (ΕΕΒΕ)
- European Society of Human Genetics (ESHG)

ΔΙΟΡΓΑΝΩΣΗ ΣΥΝΕΔΡΙΩΝ

1. **1st U-PGx Personalized Medicine Public day**, London, UK (6 Δεκεμβρίου 2017, <https://www.goldenhelix.org/3rd-u-pgx-personalized-medicine-public-day-patras-greece/>).
2. **5th U-PGx Personalized Medicine Day**, Liverpool, UK (21 Σεπτεμβρίου 2018, <https://www.goldenhelix.org/5th-upgx-personalized-medicine-day/>).
3. **2020 Pharmacogenomics Access and Reimbursement Symposium**, Washington DC, USA (7-8 Οκτωβρίου 2020, <https://www.goldenhelix.org/pharmacogenomics-access-reimbursement-symposium/>).
4. **7th U-PGx Personalized Medicine Day**, Ljubljana, Slovenia (24 Μαρτίου 2021, <https://www.goldenhelix.org/7th-u-pgx-personalised-medicine-day/>).

5. **U-PGx Personalized Medicine Symposium**, Leiden, the Netherlands (29-30 Μαρτίου 2022, <https://www.goldenhelix.org/u-pgx-personalised-medicine-symposium/>).

ΓΛΩΣΣΕΣ

- **Ελληνική** (Μητρική)
- **Αγγλικά** (Άριστη γνώση)
- **Γαλλικά** (Πολύ καλή γνώση)
- **Ολλανδικά** (Πολύ καλή γνώση)

ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΓΚΡΙΤΑ ΔΙΕΘΝΗ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ

1. **Mitropoulou C**, Webb AJ, Mitropoulos K, Brookes AJ, Patrinos GP. (2010). Locus-specific databases domain and data content analysis: Evolution and content maturation towards clinical use. *Hum Mutat*, **31(10)**: 1109-1116, <https://pubmed.ncbi.nlm.nih.gov/20672379/>.
2. **Mitropoulou C**, Grech G, Fenech AG, Borg J, Mitropoulos K, Vozikis A, Patrinos GP. (2012). Relevance of pharmacogenomics for developing countries in Europe: implementation in the Maltese population. *Malta Med J*, **24(3)**: 8-12, <https://www.um.edu.mt/umms/mmj/abstract0098.html?article=359>.
3. Mai Y, **Mitropoulou C**, Papadopoulou XE, Vozikis A, Cooper DN, van Schaik RH, Patrinos GP. (2014). Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. *Per Med*, **11(1)**: 15-26, <https://pubmed.ncbi.nlm.nih.gov/29751393/>.
4. Kampourakis K, Vayena E, **Mitropoulou C**, Borg J, van Schaik RH, Cooper DN, Patrinos GP. (2014). Key challenges for next generation pharmacogenomics. *EMBO Rep*, **15(5)**: 472-476, <https://pubmed.ncbi.nlm.nih.gov/24723683/>.
5. Mizzi C, **Mitropoulou C**, Mitropoulos K, Peters B, Agarwal MR, van Schaik RH, Drmanac R, Borg J, Patrinos GP. (2014). Personalized pharmacogenomics profiling using whole genome sequencing. *Pharmacogenomics*, **15(9)**: 1223-1234, <https://pubmed.ncbi.nlm.nih.gov/25141897/>.
6. Snyder SR, **Mitropoulou C**, Patrinos GP, Williams MS. (2014). Economic Evaluation of Pharmacogenomics: A Value-Based Approach to Pragmatic Decision Making in the Face of Complexity. *Public Health Genomics* **17(5-6)**: 256-264, <https://pubmed.ncbi.nlm.nih.gov/25278172/>.
7. **Mitropoulou C**, Mai Y, van Schaik RH, Vozikis A, Patrinos GP. (2014). Stakeholders analysis in pharmacogenomics and genomic medicine in Greece. *Public Health Genomics* **17(5-6)**: 280-286, <https://pubmed.ncbi.nlm.nih.gov/25228172/>.
8. **Mitropoulou C**, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, Poljakovic Z, van Schaik RH, Patrinos GP. (2015). Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly Croatian patients with atrial fibrillation. *Pharmacogenomics* **16(2)**: 137-148, <https://pubmed.ncbi.nlm.nih.gov/25616100/>.

9. Fragoulakis V, **Mitropoulou C**, van Schaik RH, Maniadakis N, Patrinos GP. (2016). An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. **OMICS**. 20(5):274-282, <https://pubmed.ncbi.nlm.nih.gov/27096406/>.
10. Mizzi C, Dalabira E, Kumuthini J, Dzimir N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, **Mitropoulou C**, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, McLeod HL, van der Spek PJ, Patrinos GP. (2016). A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics. **PLoS One**. 11(9): e0162866. Erratum in **PLoS One**. 12(2): e0172595, <https://pubmed.ncbi.nlm.nih.gov/27636550/>.
11. Vozikis A, Cooper DN, **Mitropoulou C**, Kambouris ME, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP. (2016). Test pricing and reimbursement in Genomic Medicine: Towards a general strategy. **Public Health Genomics** 19(6): 352-363, <https://pubmed.ncbi.nlm.nih.gov/27676083/>.
12. **Mitropoulou C**, Fragoulakis V, Rakicevic LB, Novkovic MM, Vozikis A, Matic DM, Antonijevic NM, Radojkovic DP, van Schaik RH, Patrinos GP. (2016). Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. **Pharmacogenomics** 17(16): 1775-1784, <https://pubmed.ncbi.nlm.nih.gov/27767438/>.
13. van der Wouden CH, Swen JJ, Samwald M, **Mitropoulou C**, Schwab M, Guchelaar HJ. (2016). A brighter future for the implementation of pharmacogenomic testing. **Eur J Hum Genet**. 24(12): 1658-1660, <https://pubmed.ncbi.nlm.nih.gov/27577544/>.
14. Viennas E, Komianou A, Mizzi C, Stojiljkovic M, **Mitropoulou C**, Muilu J, Vihinen M, Grypioti P, Papadaki S, Pavlidis C, Zukic B, Katsila T, van der Spek PJ, Pavlovic S, Tzimas G, Patrinos GP. (2017). Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies. **Nucleic Acids Res** 45(D1): D846-D853, <https://pubmed.ncbi.nlm.nih.gov/27924022/>.
15. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, **Mitropoulou C**, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. **Clin Pharmacol Ther**. 101(3): 341-358, <https://pubmed.ncbi.nlm.nih.gov/28027596/>.

16. Fragoulakis V, **Mitropoulou C**, Katelidou D, van Schaik RH, Maniadakis N, Patrinos GP. (2017). Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. *OMICS*. **21(2)**: 67-73, <https://pubmed.ncbi.nlm.nih.gov/28118098/>.
17. Patrinos GP, **Mitropoulou C**. (2017). Measuring the value of pharmacogenomics evidence. *Clin Pharmacol Ther*. **102(5)**: 739-741, <https://pubmed.ncbi.nlm.nih.gov/28581028/>.
18. Balasopoulou A, Mooy FM, Baker DJ, **Mitropoulou C**, Skoufas E, Bulgiba A, Katsila T, Patrinos GP. (2017). Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia. *OMICS*. **21(12)**: 733-740, <https://pubmed.ncbi.nlm.nih.gov/29173101/>.
19. Mitropoulos K, Cooper DN, **Mitropoulou C**, Agathos S, Reichardt JKV, Al-Maskari F, Chantratita W, Wonkam A, Dandara C, Katsila T, Lopez-Correa C, Ali BR, Patrinos GP. (2017). Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy. *OMICS*. **21(11)**: 647-657, <https://pubmed.ncbi.nlm.nih.gov/29140767/>.
20. Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos JGS, Martínez-González LJ, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali BR, Wordsworth S, Dávila-Fajardo CL, Katsila T, Patrinos GP, **Mitropoulou C**. (2019). Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. *Pharmacogenomics J*. **19(5)**: 438-445, <https://pubmed.ncbi.nlm.nih.gov/30647444/>.
21. Giannopoulou E, Katsila T, **Mitropoulou C**, Tsermpini EE, Patrinos GP. (2019). Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow. *Front Pharmacol*. **10**: 384, <https://pubmed.ncbi.nlm.nih.gov/31024324/>.
22. Fragoulakis V, Roncato R, Fratte CD, Ecça F, Bartsakoulia M, Innocenti F, Toffoli G, Cecchin E, Patrinos GP, **Mitropoulou C**. (2019). Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity. *Am J Hum Genet*. **104(6)**: 1158-1168, <https://pubmed.ncbi.nlm.nih.gov/31155283/>.
23. Snyder SR, Hao J, Cavallari LH, Geng Z, Elsey A, Johnson JA, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, **Mitropoulou C**, Williams MS. (2019). Generic cost-effectiveness models: A proof of concept of a tool for informed decision-making for public health precision medicine. *Public Health Genomics* **21(5-6)**: 217-227, <https://pubmed.ncbi.nlm.nih.gov/31189173/>.
24. Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, **Mitropoulou C**, Patrinos GP. (2019). Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions. *Front Pharmacol*. **10**: 830, <https://pubmed.ncbi.nlm.nih.gov/31427963/>.
25. van der Wouden CH, Böhringer S, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VHM, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, **Mitropoulou C**, Patrinos GP, Pirmohamed M, Rial-Sebbag E, Samwald M, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, van Zwet E, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. (2020). Generating evidence for precision medicine: considerations made by the Ubiquitous

- Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. *Pharmacogenet Genomics*. 30(6):131-144, <https://pubmed.ncbi.nlm.nih.gov/32317559/>.
26. **Mitropoulou C**, Litinski V, Kabakchiev B, Rogers S, P Patrinos GP. (2020). PARC report: health outcomes and value of personalized medicine interventions: impact on patient care. *Pharmacogenomics*. 21(11):797-807, <https://pubmed.ncbi.nlm.nih.gov/32635813/>.
27. Siamoglou S, Karamperis K, **Mitropoulou C**, Patrinos GP. (2020). Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing. *J Appl Lab Med*. 5(5):1005-1016, <https://pubmed.ncbi.nlm.nih.gov/32916714/>.
28. Patrinos GP, Pasparakis E, Koiliari E, Pereira AC, Hünemeier T, Pereira LV, **Mitropoulou C**. (2020). Roadmap for Establishing Large-Scale Genomic Medicine Initiatives in Low- and Middle-Income Countries. *Am J Hum Genet*. 107(4):589-595, <https://pubmed.ncbi.nlm.nih.gov/33007198/>.
29. Siamoglou S, Koromina M, Moy FM, **Mitropoulou C**, Patrinos GP, Vasileiou K. (2021). What Do Students in Pharmacy and Medicine Think About Pharmacogenomics and Personalized Medicine Education? Awareness, Attitudes, and Perceptions in Malaysian Health Sciences. *OMICS*. 25(1):52-59, <https://pubmed.ncbi.nlm.nih.gov/33170085/>.
30. Mathuba B, Koromina M, **Mitropoulou C**, Patrinos GP. (2021). Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa. *Pharmacogenomics*. 22(2):115-122, <https://pubmed.ncbi.nlm.nih.gov/33353428/>.
31. Runcharoen C, Fukunaga K, Sensorn I, Iemwimangsa N, Klumsathian S, Tong H, Vo NS, Le L, Hlaing TM, Thant M, Zain SM, Mohamed Z, Pung YF, Capule F, Nevado J Jr, Silao CL, Al-Mahayri ZN, Ali BR, Yuliwulandari R, Prayuni K, Zahroh H, Noor DAM, Xangsayarath P, Xayavong D, Kounnavong S, Sayasone S, Kordou Z, Liopetas I, Tsikrika A, Tsermpini EE, Koromina M, **Mitropoulou C**, Patrinos GP, Kesornsit A, Charoenyingwattana A, Wattanapokayakit S, Mahasirimongkol S, Mushiroda T, Chantratita W. (2021). Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). *Hum Genome Var*. 8(1):7, <https://pubmed.ncbi.nlm.nih.gov/33542200/>.
32. Siamoglou S, Koromina M, Politopoulou K, Samiou CG, Papadopoulou G, Balasopoulou A, Kanavos A, **Mitropoulou C**, Patrinos GP, Vasileiou K. (2021). Attitudes and Awareness Toward Pharmacogenomics and Personalized Medicine Adoption Among Health Sciences Trainees: Experience from Greece and Lessons for Europe. *OMICS*. 25(3):190-199, <https://pubmed.ncbi.nlm.nih.gov/33646050/>.
33. Yuliwulandari R, Shin JG, Kristin E, Suyatna FD, Prahasto ID, Prayuni K, Mahasirimongkol S, Cavallari LH, **Mitropoulou C**, Patrinos GP, Hao J, Williams MS, Snyder SR. (2021). Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model. *Pharmacogenomics J*. 21(4):476-483, <https://pubmed.ncbi.nlm.nih.gov/33824430/>.

34. Rogers SL, Patrinos GP, **Mitropoulou C**, Formea CM, Jones JS, Brown BG. (2021). Inaugural Pharmacogenomics Access and Reimbursement Symposium. *Pharmacogenomics*. 22(9):515-517, <https://pubmed.ncbi.nlm.nih.gov/34032472/>.
35. Koromina M, Fanaras V, Baynam G, **Mitropoulou C**, Patrinos GP. (2021). Ethics and equity in rare disease research and healthcare. *Per Med*. 18(4):407-416, <https://pubmed.ncbi.nlm.nih.gov/34085867/>.
36. Karamperis K, Tsoumpeli MT, Kounelis F, Koromina M, **Mitropoulou C**, Moutinho C, Patrinos GP. (2021). Genome-based therapeutic interventions for β -type hemoglobinopathies. *Hum Genomics*. 15(1):32, <https://pubmed.ncbi.nlm.nih.gov/34090531/>.
37. Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, Vozikis A, Müller DJ, Patrinos GP, **Mitropoulou C**. (2021). Economic evaluation in psychiatric pharmacogenomics: a systematic review. *Pharmacogenomics J*. 21(4):533-541, <https://pubmed.ncbi.nlm.nih.gov/34215853/>.
38. Rogers SL, Patrinos GP, **Mitropoulou C**, Formea CM, Shawn Jones J, Brown BG. (2021). Inaugural Pharmacogenomics Access and Reimbursement Symposium. *Pharmacogenomics J*. 21(5):622-624, <https://pubmed.ncbi.nlm.nih.gov/34140646/>.
39. Koufaki M, Karamperis K, Vitsa P, Vasileiou K, Patrinos GP, **Mitropoulou C**. (2021). Adoption of pharmacogenomic testing: A marketing perspective. *Front Pharmacol*. 12:724311, <https://pubmed.ncbi.nlm.nih.gov/34603034/>.
40. Patrinos GP, **Mitropoulou C**. (2021). Horizon scanning: Teaching genomics and personalized medicine in the digital age. *OMICS*, 26(2):101-105, <https://pubmed.ncbi.nlm.nih.gov/34648717/>.
41. Pandi MT, Koromina M, Vonitsanos G, van der Spek PJ, Patrinos GP, **Mitropoulou C**. (2022). Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data. *Pharmacol Res*. 178:106187, <https://pubmed.ncbi.nlm.nih.gov/35331864/>.
42. Shaman JA, Bousman CA, **Mitropoulou C**, Padmanabhan S. (2022). Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data. Pharmacogenomics: From Bench to Bedside and Back Again. *Front Genet*. 13:878191, <https://pubmed.ncbi.nlm.nih.gov/35360856/>.
43. Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, **Mitropoulou C**, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. *Lancet*. 401(10374): 347-356, <https://pubmed.ncbi.nlm.nih.gov/36739136/>.
44. Koufaki MI, Fragoulakis V, Díaz-Villamarín X, Karamperis K, Vozikis A, Swen JJ, Dávila-Fajardo CL, Vasileiou KZ, Patrinos GP, **Mitropoulou C**. (2023). Economic evaluation of

- pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. *Hum Genomics*. 17(1): 51, <https://pubmed.ncbi.nlm.nih.gov/37287029/>.
45. Fragoulakis V, Roncato R, Bignucolo A, Patrinos GP, Toffoli G, Cecchin E, **Mitropoulou C.** (2023). Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. *Pharmacol Res*. 106949 <https://pubmed.ncbi.nlm.nih.gov/37802427/>.
 46. Fragoulakis V, Koufaki NI, Tzerefou K, Koufou K, Patrinos GP, **Mitropoulou C.** (2024). Assessing the utility measurement methods applied in the economic evaluation of pharmacogenomics applications. *Pharmacogenomics*. 25(2):79-95, <https://pubmed.ncbi.nlm.nih.gov/38288576/>.
 47. Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, Ferentinos P, Bartsakoulia M, Katsila T, **Mitropoulou C**, Patrinos GP; Consortium of the PREPARE study in Greece. (2024). Clinical implementation of preemptive pharmacogenomics in psychiatry. *Lancet EBioMedicine*. 101:105009, <https://pubmed.ncbi.nlm.nih.gov/38364700/>.
 48. Fragoulakis V, Koufaki MI, Joefield-Roka C, Sunder-Plassmann G, **Mitropoulou C.** (2024). Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study. *Pharmacogenomics J*. 24(2):10, <https://pubmed.ncbi.nlm.nih.gov/38499549/>.
 49. Psatha A, Al-Mahayri ZN, **Mitropoulou C**, Patrinos GP. (2024). Meta-analysis of genomic variants in power and endurance sports to decode the impact of genomics on athletic performance and success. *Hum Genomics*. 18(1):47, <https://pubmed.ncbi.nlm.nih.gov/38760851/>.
 50. Deininger KM, Anderson HD, Patrinos GP, **Mitropoulou C**, Aquilante CL. (2024). Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data. *Pharmacogenomics J*. 24(3):14, <https://pubmed.ncbi.nlm.nih.gov/38750044/>.
 51. Fragoulakis V, Koufaki MI, Mlinšek G, Blagus T, Klen J, Patrinos GP, Dolžan V, **Mitropoulou C.** (2025). Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study. *Pharmacogenomics J*. 25(1-2):6, <https://pubmed.ncbi.nlm.nih.gov/40064851/>

BIBΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ

Αριθμός αναφορών: 1919 (Google Scholar)

H-index: 23 (Google Scholar)

Link: <https://scholar.google.com/citations?hl=en&user=MxFJ9vEAAA>

ΕΠΙΣΤΗΜΟΝΙΚΑ ΒΙΒΛΙΑ ΚΑΙ ΣΥΓΓΡΑΜΑΤΑ

1. Fragoulakis V, **Mitropoulou C**, Williams MS, Patrinos GP. (auth). (2015). [Economic Evaluation in Genomic Medicine](#). Elsevier/Academic Press, Burlington, CA, USA, ISBN 978-0128014974.
2. **Μητροπούλου Χ**, Βασιλείου Κ, Βοζίκης Α (2022). [Οικονομική Αξιολόγηση υπηρεσιών υγείας](#). Επιστημονικές Εκδόσεις Παρισιάνου Α.Ε., Αθήνα, ISBN 9789605836337 (Κωδικός [ΕΥΔΟΞΟΣ: 102183666](#)).
3. **Mitropoulou C**, Wordsworth S, Buchanan J, Patrinos GP (eds). (2023). [Economic evaluation of Genomic and Precision Medicine](#). Elsevier/Academic Press, Burlington, CA, USA, ISBN 9780128133828.

ΚΕΦΑΛΑΙΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΒΙΒΛΙΑ

1. Squassina A, Manchia M, **Mitropoulou C**, Patrinos GP. (2015). An introduction to Pharmacogenomics and Personalized Medicine, In Lanzer P (ed) PanVascular Medicine (2nd edition), Springer, Heidelberg, GERMANY, pg. 1053-1065.
2. Mpitsakos A, **Mitropoulou C**, Katsila T, Patrinos GP. (2018). Economic Evaluation and Cost-Effectiveness Analysis of Genomic Medicine Interventions in Developing and Emerging Countries. In Correa-Lopez C, Patrinos GP (eds). Genomic Medicine in developing and emergin economies. Elsevier/Academic Press, Burlington, CA, USA, pg. 145-157.
3. Cooper DN, **Mitropoulou C**, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Macek M, Mitropoulos K, Al-Mulla F, Prainsack B, van Schaik RH, Squassina A, Taruscio D, Vayena E, Vozikis A, Williams MS, Ylstra B, Patrinos GP. (2018). The Genomic Medicine Alliance: A Global Effort to Facilitate the Introduction of Genomics into Healthcare in Developing Nations. In Correa-Lopez C, Patrinos GP (eds). Genomic Medicine in developing and emerging economies. Elsevier/Academic Press, Burlington, CA, USA, pg. 173-188.
4. **Mitropoulou C**, Politopoulou K, Vozikis A, Patrinos GP. (2019). Assessing the stakeholders' landscape and stance point in Genomic and Personalized Medicine. In Patrinos GP (ed). Applied Genomics and Public Health. Elsevier/Academic Press, Burlington, CA, USA, pg. 211-234.
5. Fragoulakis V, Patrinos GP, **Mitropoulou C**. (2019). Economic evaluation of Genomic and Personalized Medicine interventions: Implications for public health. In Patrinos GP (ed). Applied Genomics and Public Health. Elsevier/Academic Press, Burlington, CA, USA, pg. 287-304.
6. **Mitropoulou C**, Fragoulakis V, Vozikis A, Patrinos GP. (2019). Pricing, budget allocation and reimbursement of Personalized Medicine intereventions. In Patrinos GP (ed). Applied Genomics and Public Health. Elsevier/Academic Press, Burlington, CA, USA, pg. 305-314.

7. **Mitropoulou C**, Giannouri D, Karamperis K, Wedge S, Patrinos GP. (2019). Defining genetic testing delivery and promotional strategies for Personalized Medicine. In Patrinos GP (ed). Applied Genomics and Public Health. Elsevier/Academic Press, Burlington, CA, USA, pg. 329-344.

ΑΝΤΑΓΩΝΙΣΤΙΚΗ ΧΡΗΜΑΤΟΔΟΤΗΣΗ

ΤΡΕΧΟΥΣΑ ΧΡΗΜΑΤΟΔΟΤΗΣΗ

1. Ευρωπαϊκή Επιτροπή 01/10/2024 – 30/04/2028
Acronym/Αριθμός Συμβολαίου: Horizon Europe-GoE
Έργο: “Genome of Europe”.
Ρόλος: **Co-investigator and co-financing entity.**
Ποσό: **35,000 EUR.**

ΠΕΡΑΤΩΘΕΙΣΑ ΧΡΗΜΑΤΟΔΟΤΗΣΗ

1. Ευρωπαϊκή Επιτροπή 01/09/2019 – 30/04/2024
Acronym/Αριθμός Συμβολαίου: H2020-TranSYS (860895)
Έργο: “[Translational Systemics: Precision Medicine at the interface of Translational research and Systems Medicine](#)”.
Ρόλος: **Co-investigator.**
Ποσό: **302,493 EUR.**
2. UAE Ministry of Education 01/01/2021 – 31/12/2023
Acronym/Αριθμός Συμβολαίου: Em-HEART (CRPG2019-1570604941)
Έργο: “Individualizing cardiovascular disease treatment modalities in the UAE using a genomics-based approach”.
Ρόλος: **Co-Investigator.**
Ποσό: **101499 EUR (600,000.00 AED).**
3. Ευρωπαϊκή Επιτροπή 01/01/2016 – 31/12/2021
Acronym/Αριθμός Συμβολαίου: H2020-U-PGx (668353)
Έργο: “[Ubiquitous Pharmacogenomics: Making effective treatment optimization accessible to every European citizen](#)”.
Ρόλος: **Co-investigator, Member of the Executive Board and WP5 and WP11 Leader**
Ποσό: **725,000 EUR.**
4. Ευρωπαϊκή Επιτροπή 01/11/2013 – 31/10/2017
Acronym/Αριθμός Συμβολαίου: COST-CHIP_ME (IS1303)
Έργο: “[Citizen’s Health through public-private initiatives: Public Health, Market and Ethical perspectives](#)”.
Ρόλος: **Member.**
Ποσό: **15,000 EUR.**

5. Ευρωπαϊκή Επιτροπή 01/06/2013 – 31/12/2015
Acronym/Αριθμός Συμβολαίου: REGPOT-2012-2013-1-SERBORDISinn
Έργο: “Strengthening the Research Potential of IMGGE through Reinforcement of Biomedical Science of Rare Diseases in Serbia – en route for innovation”.
Ρόλος: **Co-investigator**
Ποσό: **15,000 EUR.**